Jnana Therapeutics announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, is being evaluated as a potential first-in-class oral treatment for PKU across all ages and genotypes. Based on these positive mid-term results, Jnana has adjusted its phase 1b clinical trial design to support the critical phase 3 clinical trial of JNT-517 starting in the first half of 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.